ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
12 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with renal...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
11 mai 2023 09h07 HE
|
ZyVersa Therapeutics
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
09 mai 2023 09h05 HE
|
ZyVersa Therapeutics
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
04 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
01 mai 2023 18h30 HE
|
ZyVersa Therapeutics
WESTON, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
27 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS...
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
26 avr. 2023 09h10 HE
|
ZyVersa Therapeutics
WESTON, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
25 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
24 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical...
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
19 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia ...